NCT07039890View on ClinicalTrials.gov

To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 8, 2025

Primary Completion Date

May 14, 2025

Study Completion Date

June 5, 2025

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Empagliflozin + Linagliptin filmcoated tablets

Empagliflozin + Linagliptin 10 mg/5 mg filmcoated tablets

DRUG

Glyxambi film-coated tablets

Glyxambi 10 mg/5 mg film-coated tablets

Trial Locations (1)

382210

Veeda Clinical Research Ltd., Ahmedabad

All Listed Sponsors
lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT07039890 - To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions. | Biotech Hunter | Biotech Hunter